Eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) are
n-3 fatty acids found in oily fish and
fish oil supplements. These
fatty acids are able to inhibit partly a number of aspects of
inflammation including leucocyte chemotaxis, adhesion molecule expression and leucocyte-endothelial adhesive interactions, production of
eicosanoids like
prostaglandins and
leukotrienes from the
n-6 fatty acid arachidonic acid, production of inflammatory
cytokines and T cell reactivity. In parallel, EPA gives rise to
eicosanoids that often have lower biological potency than those produced from arachidonioc
acid and EPA and DHA give rise to anti-inflammatory and
inflammation resolving resolvins and protectins. Mechanisms underlying the anti-inflammatory actions of
n-3 fatty acids include altered cell membrane
phospholipid fatty acid composition, disruption of
lipid rafts, inhibition of activation of the pro-inflammatory
transcription factor nuclear factor kappa B so reducing expression of inflammatory genes, activation of the anti-inflammatory
transcription factor NR1C3 (i.e.
peroxisome proliferator activated receptor γ) and binding to the
G protein coupled receptor GPR120. These mechanisms are interlinked. In adult humans, an EPA plus DHA intake greater than 2 g day⁻¹ seems to be required to elicit anti-inflammatory actions, but few dose finding studies have been performed. Animal models demonstrate benefit from
n-3 fatty acids in
rheumatoid arthritis (RA),
inflammatory bowel disease (IBD) and
asthma. Clinical trials of
fish oil in patients with RA demonstrate benefit supported by meta-analyses of the data. Clinical trails of
fish oil in patients with IBD and
asthma are inconsistent with no overall clear evidence of efficacy.